Journal of Advanced Pharmaceutical Technology & Research

: 2020  |  Volume : 11  |  Issue : 3  |  Page : 113--116

Antibiotic resistance: Evaluation of levofloxacin treatment in acute respiratory tract infections cases at the Tasikmalaya City Health Center, Indonesia

Danni Ramdhani1, Shinta Nur Azizah1, Sri Agung Fitri Kusuma2, Dede Sediana3,  
1 Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Bandung, Sumedang, Indonesia
2 Department of Pharmaceutical Biology, Faculty of Pharmacy, Padjadjaran University, Bandung, Sumedang, Indonesia
3 Pharmaceutical Division, Tasikmalaya City Health Office, West Java Province, Indonesia

Correspondence Address:
Mr. Danni Ramdhani
Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Padjadjaran University, Bandung, West Java


Acute respiratory tract infections (ARTIs) are an acute inflammation of the upper and lower respiratory tract caused by the infection of microorganisms or bacteria, viruses, without or accompanied by inflammation of the lung parenchyma. The use of antibiotics is one way to treat respiratory diseases. This study aims to determine the level of resistance of levofloxacin antibiotics to clinical isolates from ARTIs patients at the Tasikmalaya Health Center, Indonesia. The stages of the research included rejuvenation of clinical single isolates from ARTIs patients, identification of bacteria, and antibiotic resistance testing using the paper-disc method. The results of resistance tests from 142 single clinical isolates of acute respiratory infections showed that levofloxacin antibiotics had high levels of resistance of 50.0%, 30.95% of resistance with intermediate levels, and 19.04% were still sensitive. Bacterial identification test results showed bacteria that have been resistant to levofloxacin are from the genus Haemophillus, Streptococcus, Corynebacterium, Staphylococcus, and Bordetella. Treatment of ARTIs with the antibiotic levofloxacin shows that there has been a relatively large resistance, where the results of the identification of all bacteria showed the bacteria that cause ARTIs.

How to cite this article:
Ramdhani D, Azizah SN, Kusuma SA, Sediana D. Antibiotic resistance: Evaluation of levofloxacin treatment in acute respiratory tract infections cases at the Tasikmalaya City Health Center, Indonesia.J Adv Pharm Technol Res 2020;11:113-116

How to cite this URL:
Ramdhani D, Azizah SN, Kusuma SA, Sediana D. Antibiotic resistance: Evaluation of levofloxacin treatment in acute respiratory tract infections cases at the Tasikmalaya City Health Center, Indonesia. J Adv Pharm Technol Res [serial online] 2020 [cited 2020 Aug 9 ];11:113-116
Available from:

Full Text


Acute respiratory tract infections (ARTIs) are one of the main causes of morbidity and mortality in developing countries.[1],[2] In Indonesia, ARTIs cause mortality of 28% in infants and 15.5% of them are pneumonia.[3] Complaints of this disease are one of the main reasons patients consult a doctor, and also more than 60% the reason for the use of antibiotics.[4] The bacteria that commonly cause ARTIs include Streptococcus haemoliticus, Staphylococcus, Pneumococcus, Haemophilus influenzae, Bordetella pertussis, and Corynebacterium diphtheria.[5] Monitoring in prescribing by doctors and patient compliance in taking antibiotics is an important factor in increasing antibiotic resistance.[6]

Monitoring of antibiotic resistance cases in the city of Tasikmalaya, Indonesia, reported the cases of resistance in the treatment of ARTIs, namely 43.03% resistant to ciprofloxacin, cefadroxil 43.03%, and antibiotic amoxicillin 70.25%. Research data were obtained from more than 300 throat swabs from the patients indicated as having ARTIs.[7],[8]

This study aims to evaluate the effectiveness of levofloxacin antibiotics in the treatment of cases of ARTIs. This study uses clinical isolates from the patients obtained from previous studies.

 Materials and Methods

Clinical isolate samples from previous studies were rejuvenated, and identification was carried out to determine the purity of clinical isolates in accordance with microbiological standards.

Clinical isolate rejuvenation

Clinical isolate samples were inoculated using Ose to the surface of new Mueller Hinton agar (MHA) growth media and incubated at 37°C for 18 h. After that, the identification of bacteria, which includes morphological parameters of the colony: Color, structure of the colony, as well as different hemolytic and morphological characteristics.

Identification of bacteria

Bacterial identification of clinical isolates was carried out by observing bacterial morphology, Gram staining, and biochemical tests. Biochemical tests conducted were a motility test, carbohydrate fermentation test (glucose, maltose, lactose, manose, and saccharose), indole test, triple sugar iron agar (TSIA) test, urease test, methyl red (MR) test, Voges proskauer test, and citrate test.[9]

Antibiotic resistance test

Antibiotic resistance testing uses the agar diffusion method with paper-disc techniques. Levofloxacin antibiotics are made standard solutions with a concentration of 10 μg/mL. The bacterium used for this test is Staphylococcus aureus. Resistance test results are obtained by comparing the inhibition zone formed with the standard diameter of the resistant inhibition zone.[10]

 Results and Discussion

Bacteria identification results

This test was carried out to determine the bacterial genus contained in clinical isolates, which included its morphological form, Gram staining test, and biochemical tests.

Bacterial morphological test results

Samples from clinical isolates were grouped into five based on their morphological colonies. Morphological test results from five groups of clinical isolates are shown in [Table 1].{Table 1}

Gram staining results

Gram staining test is performed to determine the type of Gram-positive or Gram-negative bacteria. Gram-positive bacteria will turn purple (violet crystals) due to the complex of violet-iodine crystalline dyes being maintained, even though they are given a water-coloring solution to compare fucsin or safranin. While Gram-negative bacteria will be colored red (safranin), this is due to the loss of violet crystal dyes after washing with alcohol.[11] Gram staining test results from the bacterial group are shown in [Table 2].{Table 2}

Biochemical test results

Biochemical tests aim to identify the bacteria in a single-colony isolate sample based on its physiological properties. These physiological properties are related to biochemical activities that occur through bacterial cell metabolism. Biochemical tests carried out in bacterial identification include sugar test (glucose, maltose, mannose, saccharose, and lactose), MR, Vogers-Proskauerindole, urea, motility, TSIA, and Simmon Citrate.[11] The results of biochemical testing of the bacterial group are shown in [Table 3].{Table 3}

Resistance test results for levofloxacin antibiotics

Resistance test is a test to determine the activity of bacteria to survive the effects of antibiotics. This test uses a paper-disk method with a sample of clinical bacterial isolates from the mouth smears of patients diagnosed with ARTIs.[12]

The media used for testing this resistance is MHA. This media was chosen because MHA is very good and sensitive to antimicrobial activity. In addition, MHA media provide good and reproducible results. The levofloxacin antibiotic concentration used for this test was 30 μg/mL.[13]

Evaluation of the results of the resistance test is seen from the calculation of the diameter of the inhibitory zone formed due to antibiotic activity. This inhibition zone is a place where bacteria are stunted due to antibacterial activity or antibiotics.[13] Bacterial growth inhibition zone diameter indicates bacterial sensitivity to antibiotics. Inhibition zone measurement results will be compared with the literature to determine the classification of the bacteria tested. The bacterial classification is divided into resistant, intermediate, and sensitive.

The results of resistance test against clinical isolate bacterial samples showed that as many as 50% of bacterial samples were resistant; 30.95% intermediates, and 19.04% are still sensitive. 13] The results of the resistance test are shown in [Figure 1].{Figure 1}

The graph shows a decrease in the ability of levofloxacin antibiotics to inhibit the growth of bacteria originating from the isolates of ARTIs patients at the health center in the city of Tasikmalaya, Indonesia. This condition can be caused by various factors, including prescription of irrational antibiotics and patient compliance in the use of antibiotics so that it can affect the increase in resistance.[14]


The results of the study can be concluded that there has been a case of resistance to the use of antibiotics levofloxacin in the handling cases of ARTIs in the city of Tasikmalaya. The results showed that about 50% of the antibiotic resistance conditions had occurred levofloxacin. Intermediate conditions of 30.95% can develop into resistance. While only 19.04% of levofloxacin antibiotics are still effective in treating ARTIs.

The results of bacterial identification show that bacteria resistant to levofloxacin are from the genus Haemophillus, Streptococcus, Corynebacterium, Staphylococcus, and Bordetella. The identification of this bacterial genus is in accordance with the literature, which causes ARTIs.[15]


The authors declare that there are no conflicts of interest regarding the publication of this paper. The author thanks to Shinta Nur Azizah for her cooperation in this research.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Navneeth BV, Belwadi MR, Sandhya B. Antibiotic resistance among Gram-negative bacteria of lower respiratory tract secretion in hospitalised patients. Indian J Chest Dis Allied Sci 2002;44:173-6.
2Pittet D. Nosocomial pneumonia: Incidence, morbidity and mortality in the intubated-ventilated patients. Schweiz Med Woechensch 1994;124:227-35.
3West Java Pronvincial Health Office (Indonesia). Report on Basic Health Research Results (Riskesdas) West Java Province. Bandung: West Java Provincial Health Office; 2007. p. 57-62.
4Petersen I, Hayward AC. Antibacterial prescribing in primary care. J. Antimicrob Chemother 2007;60:437.
5World Health Organization. Word Health. Part III. Global Health Indicators. World Health Organization; 2014. Available from: [Last accessed on 2020 Feb 19].
6Adriaenssens N, Coenen S, Versporten A, Muller A, Vankerckhoven V, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): Quality appraisal of antibiotic use in Europe. J Antimicrob Chemother 2011:66;71-7.
7Ramdhani D, Fitrikusuma SA, Afifi, Mustarichie R. Amoxilin resistance in the area of Tasikmalaya, West Java. J Chem Pharm Res 2016;8:873-8.
8Ramdhani D, Alfaeira, CH, Kusuma SA. Ciprofloxacin resistance among clinical isolates from acute respiratory infections (ARIs) patient at Community Health Centers in Tasikmalaya, Indonesia. Asian J Pharm Clin Res 2017;10:42.
9Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobia Susceptibility Testing; Twenty-Fourth Informational Supplement. USA: Clinical and Laboratory Standards Institute; 2014. p. 68-76.
10Holt JG, Krieg NR, Sneath PH, Staley JT, Williams ST. Bergey's Manual of Determinative Bacteriology. 9th ed. United Stated of America: Williams and Wilkins; 1994.
11Lalitha M. Manual on antimicrobial susceptibility testing. In: Performance Standards for Antimicrobial Testing: Twelfth Informational Supplement. Vol. 56238. Wayne, PA, USA: CLSI; 2004. p. 454-6.
12Reller LB, Weinstein M, Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clin Infect Dis 2009;49:1749-55.
13Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS). Providing NCCLS Standards and Guidelines; 2004.
14Meropol SB, Localio AR, Metlay JP. Risks and benefits associated with antibiotic use for acute respiratory infections: A cohort study. Ann Fam Med 2013;11:165-72.
15Dasaraju PV, Liu C. Infections of the respiratory system. In: Baron S, editor. Medical Microbiology. 4th ed., Ch. 93. Galveston, TX, USA: University of Texas Medical Branch at Galveston; 1996.